TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

QR Code

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...

Full description

Saved in:

Bibliographic Details
Main Authors:	E N Aleksandrova, E Yu Panasyuk, A S Avdeyeva, A A Novikov, G V Lukina, M V Cherkasova, N V Klimova, E L Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2011-06-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies
Online Access:	https://rsp.mediar-press.net/rsp/article/view/705
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bone destruction in rheumatoid arthritis: role of autoantibodies
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2013-06-01)

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Elena Nikolayevna Aleksandrova, et al.
Published: (2012-02-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
by: V. V. Badokin, et al.
Published: (2011-06-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
by: E. L. Nasonov
Published: (2017-04-01)

EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS
by: Yu. V. Muravyev
Published: (2018-07-01)

Anti-cyclic citrullinated peptide antibodies – a role in rheumatoid arthritis and the possibility of seroconversion: A focus on abatacept
by: N. V. Chichasova
Published: (2017-03-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Relation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data)
by: D. А. Dibrov, et al.
Published: (2024-04-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
by: I. A. Guseva, et al.
Published: (2016-03-01)

Seropositive juvenile rheumatoid arthritis: analysis of the spectrum of clinical manifestations and therapy according to a retrospective study
by: М. I. Kaleda, et al.
Published: (2021-02-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
by: A. S. Avdeeva, et al.
Published: (2022-05-01)

ACCP-negative rheumatoid arthritis – clinical and immunological features
by: D. A. Dibrov
Published: (2022-07-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
by: S O Salugina, et al.
Published: (2009-06-01)

Clinical features of ACPA-negative and ACPA-positive variants of rheumatoid arthritis
by: D. A. Dibrov, et al.
Published: (2023-04-01)

SYNOVIAL MEMBRANE CHANGES IN PATIENTS WITH RHEUMATOID ARTHRITIS REVEALED DURING ARTHROSCOPY
by: E. B. Komarova
Published: (2017-07-01)

Bone resorption during therapy with denosumab in patients with rheumatoid arthritis, positive for the main immunological markers
by: P. S. Kovalenko, et al.
Published: (2022-11-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
by: N. V. Rebrova, et al.
Published: (2022-07-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

CHANGES IN THE LEVELS OF ANGIOTENSIN II, ALDOSTERONE, AND FIBROBLAST GROWTH FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN RELATION TO CLINICAL FEATURES
by: E. B. Komarova, et al.
Published: (2016-07-01)

Relationship of immunogenetic and immunologic markers and their influence on disease activity and radiological progression in patients with early rheumatoid arthritis
by: N V Demidova
Published: (2009-06-01)

Clinical and immunological variants of ANCA-associated systemic vasculitis: a look at the pulmonary fibrosis in microscopic polyangiitis with anti-myeloperoxidase antibodies and rheumatoid factor. Literature review and own observation
by: T. V. Beketova, et al.
Published: (2023-03-01)

Role of ultrasonic examination in assessment of the knee-joint state in patients with juvenile idiopathic arthritis
by: V. O. Roschina, et al.
Published: (2012-10-01)

FEATURES OF ULTRASOUND PARAMETERS AND MARKER OF ANGIOGENESIS IN PATIENTS WITH RHEUMATOID ARTHRITIS DEPENDING OF THE LEVEL ANTI-CCP
by: E. B. Komarova, et al.
Published: (2015-12-01)

Antibodies against post-translationally modified vimentin peptides in patients with rheumatoid arthritis
by: P. A. Kuznetsova, et al.
Published: (2017-09-01)

CLINICAL IMPORTANCE OF DETERMINATION OF HLA-DRB1 LOCUS GENES IN RHEUMATOID ARTHRITIS
by: V. Guseva, et al.
Published: (2019-05-01)

DRUG-INDUCED ENCEPHALOPATHY WITH IMPAIRED COGNITIVE FUNCTIONS DURING TOCILIZUMAB USE
by: P. A. Shesternya, et al.
Published: (2019-09-01)

Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease
by: E. L. Nasonov, et al.
Published: (2023-06-01)

INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01)

AUTOANTIBODIES TO CIRTULLINATED ANTIGENS FOR DIAGNOSIS AND PREDICTION OF CLINICAL COURSE IN EARLY RHEUMATOID ARTHRITIS
by: I. B. Belyaeva, et al.
Published: (2014-07-01)

CHARACTERISTICS OF AUTOIMMUNE INFLAMMATION IN THE PATIENTS WITH LUNG TUBERCULOSIS
by: A. A. Starshinova, et al.
Published: (2019-12-01)

Peculiarities of immunological manifestations in patients with rheumatoid arthritis in the presence of chronic infection with <i>Helicobacter pylori</i> variant encoding cytotoxin-associated gene A
by: A. V. Aleksandrov, et al.
Published: (2023-06-01)

Autoantibodies and SARS-CoV-2 infection: A case report
by: T. I. Kalenchic, et al.
Published: (2022-07-01)

EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01)

LONG-TERM SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OF MODERATE OR HIGH ACTIVITY (RESULTS OF PHASE III MULTICENTER EXTENSION CLINICAL STUDY ML28124)
by: E. L. Nasonov, et al.
Published: (2018-07-01)

Immunogenetic and immunologic markers of early rheumatoid arthritis. RADIKAL program first stage results
by: I A Guseva, et al.
Published: (2008-12-01)

PROSPECTS FOR USING TOCILIZUMAB IN SYSTEMIC SCLEROSIS
by: L. P. Ananyeva
Published: (2016-02-01)

Serum calprotectin levels: A measure of disease activity in rheumatoid arthritis
by: Pranshu Dhingra, et al.
Published: (2025-01-01)

Current state and future directions of basic research in rheumatoid arthritis
by: Byeongzu Ghang, et al.
Published: (2025-07-01)